AUTL
Autolus Therapeutics plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
Market Cap: 1.31 Billion
Primary Exchange: NASDAQ
Website: https://www.autolus.com/
Shares Outstanding: 232 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.6945311640677918
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1629 trading days
From: 2018-11-09 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|